Darya-Varia Laboratoria Tbk PT
IDX:DVLA
Darya-Varia Laboratoria Tbk PT
IDX:DVLA
Price:
1 605
IDR
0.31%
Market Closed
Market Cap:
Rp1.8T
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
Darya-Varia Laboratoria Tbk PT
IDX:DVLA
|
ID |
|
T
|
Trive Property Group Bhd
KLSE:TRIVE
|
MY |
|
C
|
Cover Corp
TSE:5253
|
JP |
|
Livetiles Ltd
ASX:LVT
|
AU |
|
H
|
Hwail Pharm Co Ltd
KOSDAQ:061250
|
KR |
|
China Glass Holdings Ltd
HKEX:3300
|
HK |
|
E
|
Ensign Energy Services Inc
OTC:ESVIF
|
CA |
|
Concordia Financial Group Ltd
TSE:7186
|
JP |
|
Tokai Soft Co Ltd
TSE:4430
|
JP |
|
Primax Electronics Ltd
TWSE:4915
|
TW |
|
A
|
Aloys Inc
KOSDAQ:297570
|
KR |
|
Alice Queen Ltd
ASX:AQX
|
AU |
|
W
|
Waste Connections Inc
NYSE:WCN
|
CA |
|
UTL Industries Ltd
BSE:500426
|
IN |
Multiples-Based Value
The Multiples-Based Value of one
DVLA
stock under the Base Case scenario is
hidden
IDR.
Compared to the current market price of 1 605 IDR,
Darya-Varia Laboratoria Tbk PT
is
hidden
.
Multiples-Based Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
DVLA Multiples-Based Value
LOCKED
Multiples Across Competitors
DVLA Competitors Multiples
Darya-Varia Laboratoria Tbk PT Competitors
Darya-Varia Laboratoria Tbk PT Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| ID |
|
Darya-Varia Laboratoria Tbk PT
IDX:DVLA
|
1.8T IDR | 0.8 | 10.4 | 6.1 | 6.1 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
855.1B USD | 13.1 | 41.4 | 28 | 29.9 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
574.7B USD | 5.8 | 26.8 | 17.2 | 21.9 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 4.1 | 19.6 | 11.6 | 13.1 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
230.5B GBP | 5.2 | 29.8 | 16.5 | 23.2 | |
| CH |
|
Novartis AG
SIX:NOVN
|
228.1B CHF | 5 | 20.2 | 12.5 | 16.1 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
291.8B USD | 4.4 | 15.7 | 9.8 | 11.9 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD | 105.4 | -83.6 | 386.8 | 970 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK | 3.7 | 11.1 | 8.2 | 9.6 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
154.6B USD | 2.5 | 19.9 | 7.7 | 10.2 | |
| UK |
|
GlaxoSmithKline PLC
LSE:GSK
|
86.5B GBP | 2.6 | 15.1 | 8.2 | 10.2 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
